{"transactions":[{"id":2313731,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2022-03-31T21:15:50.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":2125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":2125000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2125000},"source":{"system":"sec-edgar","filing":"0001209191-22-021794","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021794/doc4.xml","form_type":"4"}},{"id":2317374,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-28T11:00:20.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":2125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":2125000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2125000},"source":{"system":"sec-edgar","filing":"0001209191-22-021211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021211/doc4.xml","form_type":"4"}},{"id":2586098,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Restricted Stock Units","published_at":"2021-08-31T21:30:03.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":2750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning August 31, 2022, becoming fully vested on August 31, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning August 31, 2022, becoming fully vested on August 31, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning August 31, 2022, becoming fully vested on August 31, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning August 31, 2022, becoming fully vested on August 31, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning August 31, 2022, becoming fully vested on August 31, 2024, subject in each case to the continued service of the reporting person with the issuer."}],"balance_after":2750000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2750000},"source":{"system":"sec-edgar","filing":"0001209191-21-054119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121054119/doc4.xml","form_type":"4"}},{"id":2586097,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Units","published_at":"2021-08-31T21:30:03.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":2750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance stock units (PSUs) vest on August 31, 2024 based on the market capitalization of the issuer, which will be tested annually over three years beginning August 31, 2022 and are subject to the continuous service of the reporting person with the issuer.  The number of PSUs listed is the maximum number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and maximum number of PSUs, depending on the milestones achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (PSUs) vest on August 31, 2024 based on the market capitalization of the issuer, which will be tested annually over three years beginning August 31, 2022 and are subject to the continuous service of the reporting person with the issuer.  The number of PSUs listed is the maximum number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and maximum number of PSUs, depending on the milestones achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (PSUs) vest on August 31, 2024 based on the market capitalization of the issuer, which will be tested annually over three years beginning August 31, 2022 and are subject to the continuous service of the reporting person with the issuer.  The number of PSUs listed is the maximum number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and maximum number of PSUs, depending on the milestones achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (PSUs) vest on August 31, 2024 based on the market capitalization of the issuer, which will be tested annually over three years beginning August 31, 2022 and are subject to the continuous service of the reporting person with the issuer.  The number of PSUs listed is the maximum number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and maximum number of PSUs, depending on the milestones achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The performance stock units (PSUs) vest on August 31, 2024 based on the market capitalization of the issuer, which will be tested annually over three years beginning August 31, 2022 and are subject to the continuous service of the reporting person with the issuer.  The number of PSUs listed is the maximum number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and maximum number of PSUs, depending on the milestones achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":2750000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2750000},"source":{"system":"sec-edgar","filing":"0001209191-21-054119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121054119/doc4.xml","form_type":"4"}},{"id":3113557,"issuer":{"id":5478,"kind":"organization","name":"PUMA BIOTECHNOLOGY, INC.","symbol":"PBYI"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2020-06-11T20:55:20.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":25748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":25748,"source":{"system":"sec-edgar","filing":"0001209191-20-036168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000120919120036168/doc4.xml","form_type":"4"}},{"id":3159894,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:05:45.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":354632,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":2.65,"underlying":"Common Stock","underlying_shares":354632},"source":{"system":"sec-edgar","filing":"0001694187-20-000062","document":"wf-form4_158881352702970.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418720000062/wf-form4_158881352702970.xml","form_type":"4"}},{"id":3159893,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:05:45.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":6.13,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001694187-20-000062","document":"wf-form4_158881352702970.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418720000062/wf-form4_158881352702970.xml","form_type":"4"}},{"id":3159892,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:05:45.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":208062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":10.2,"underlying":"Common Stock","underlying_shares":208062},"source":{"system":"sec-edgar","filing":"0001694187-20-000062","document":"wf-form4_158881352702970.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418720000062/wf-form4_158881352702970.xml","form_type":"4"}},{"id":3159891,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-06T21:05:45.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":776085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive 0.063 (the \"Exchange Ratio\") of American Depositary Shares of BioNTech (\"BioNTech ADS\") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 306,667 restricted stock units (each, an \"RSU\") held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive 0.063 (the \"Exchange Ratio\") of American Depositary Shares of BioNTech (\"BioNTech ADS\") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 306,667 restricted stock units (each, an \"RSU\") held by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001694187-20-000062","document":"wf-form4_158881352702970.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418720000062/wf-form4_158881352702970.xml","form_type":"4"}},{"id":3238456,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-02T18:38:40.000Z","date":"2020-02-29","kind":"tax_withholding","acquired":false,"shares":9783,"price":1.5,"value":14674.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on February 27, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 29, 2020."}],"balance_after":776085,"source":{"system":"sec-edgar","filing":"0001694187-20-000027","document":"wf-form4_158319230327755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418720000027/wf-form4_158319230327755.xml","form_type":"4"}},{"id":3312691,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-13T17:20:41.000Z","date":"2020-01-12","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. O'Dowd was awarded 240,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on January 31, 2021 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":785868,"source":{"system":"sec-edgar","filing":"0001694187-20-000007","document":"wf-form4_157895402278621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418720000007/wf-form4_157895402278621.xml","form_type":"4"}},{"id":3392108,"issuer":{"id":5478,"kind":"organization","name":"PUMA BIOTECHNOLOGY, INC.","symbol":"PBYI"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-17T17:01:25.000Z","date":"2019-10-15","kind":"grant","acquired":true,"shares":85201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date (\"Vesting Commencement Date\") of the option is October 15, 2019. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":85201,"derivative":{"exercise_price":6.79,"expiration_date":"2029-10-14","underlying":"Common Stock","underlying_shares":85201},"source":{"system":"sec-edgar","filing":"0001209191-19-053442","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000120919119053442/doc4.xml","form_type":"4"}},{"id":3623411,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-01T18:18:47.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019."}],"balance_after":200000,"derivative":{"exercise_price":6.13,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001694187-19-000012","document":"wf-form4_155148231316587.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418719000012/wf-form4_155148231316587.xml","form_type":"4"}},{"id":3623410,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-03-01T18:18:47.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. O'Dowd was awarded 100,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":545868,"source":{"system":"sec-edgar","filing":"0001694187-19-000012","document":"wf-form4_155148231316587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000169418719000012/wf-form4_155148231316587.xml","form_type":"4"}},{"id":3836108,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-22T16:18:46.000Z","date":"2018-08-20","kind":"exercise","acquired":false,"shares":18868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vested on September 23, 2017, with the remainder vesting over 36 equal monthly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the shares vested on September 23, 2017, with the remainder vesting over 36 equal monthly installments thereafter."}],"balance_after":314607,"derivative":{"exercise_price":2.65,"underlying":"Common Stock","underlying_shares":18868},"source":{"system":"sec-edgar","filing":"0001104659-18-053206","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000110465918053206/a4.xml","form_type":"4"}},{"id":3836107,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":128619,"kind":"person","name":"O'Dowd Hugh","position":1,"cik":"0001741171","reported_name":"O'Dowd Hugh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-08-22T16:18:46.000Z","date":"2018-08-20","kind":"exercise","acquired":true,"shares":18868,"price":2.65,"value":50000.2,"ownership":{"direct":true},"balance_after":445868,"source":{"system":"sec-edgar","filing":"0001104659-18-053206","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741171/000110465918053206/a4.xml","form_type":"4"}}]}